Luteolin (a flavone supplement for histamine and brain fog)

Supplements · §517

Take the flavone in parsley, chamomile, and celery, multiply by three hundred, put it in a capsule. That is the supplement — and the in-cell mechanism is unusually clean for the genre: replicated mast-cell stabilization, microglial quieting, and NF-κB inhibition across dozens of independent labs. The human trial cabinet is unusually thin: zero blinded, placebo-controlled trials in twenty years, and the open-label studies that exist were run by the patent-holder on a multi-ingredient pill. If you have flushing, hives, or histamine-driven brain fog that antihistamines only half-fix, this is a credible adjunct worth a careful try. If you don't, the parsley is doing roughly the same job at a fraction of the cost.

Decide · Daily Evidence Mixed Chapter Supplements

A few honest things are true at once. The mechanism on inflammation, mast cells, and the brain's immune cells is real and replicated. The audience is narrow — mostly people whose symptoms run through histamine — and mainstream allergy care doesn't recommend it. The evidence gap is twenty years deep and nobody is rushing to fill it. Cheap, low-effort, mostly harmless, occasionally interacts with prescription drugs in ways the label doesn't warn about. Pointed at a specific kind of person, not at everyone.

Luteolin is a yellow flavone — one of the thousands of polyphenol pigments plants make. In a cell, it does a small set of specific things the marketing names accurately. It blocks the master inflammation switch — a transcription factor called NF-κB — and the stress kinases (p38, JNK) that drive cytokine production, with downstream drops in TNF-α, IL-6, and the inflammation-related enzyme COX-2 Aziz et al. 2018. In mast cells, it blocks IgE-triggered release of histamine and tryptase at low-micromolar concentrations Kimata et al. 2000 Kempuraj et al. 2008. In microglia — the brain's immune cells — it shuts down the same JNK / AP-1 / IL-6 loop that mainstream neuroinflammation research is trying to drug pharmaceutically Jang et al. 2008. The mechanism is real. The catch is the dose that gets into your blood.

What the trials actually show

In twenty years there is not a single blinded, placebo-controlled, adequately powered randomized trial of luteolin on a clinical endpoint in humans. That sentence is the most important one to read before you decide to try it. What does exist is a 26-week open-label study of fifty children with autism spectrum disorder on a three-ingredient flavone formulation (luteolin plus quercetin plus rutin), dosed by body weight; about two-thirds of completers showed adaptive-function and behaviour gains, and the responders had measurable drops in serum TNF and IL-6 Taliou et al. 2013 Tsilioni et al. 2015. The mechanism-to-biomarker-to-behaviour chain is unusually complete for any flavonoid. The trial was also unblinded, single-arm, used a multi-ingredient pill rather than pure luteolin, and was run by the formulation's patent-holder. That doesn't make the effect placebo. It does mean nobody can tell you it wasn't.

The long-COVID brain-fog literature on luteolin is a small set of papers arguing the molecule should be tried, citing the microglial mechanism and absence of alternatives Theoharides et al. 2021. Those papers are not reports of trials; they are calls for trials that have not happened.

Community signal in mast-cell-disorder forums, chronic-urticaria patient groups, and long-COVID support communities is real and consistent in shape: a fraction of users report meaningful symptom reduction — fewer flushes, fewer post-meal reactions, less histamine-driven afternoon fog — and most report subtle or no effect. That pattern is consistent with a real but modest effect in the narrow indication the supplement is sold for. It is also consistent with placebo. Without a controlled trial, those two stories are equally defensible.

How to try it without wasting the trial

Doses in the human literature cluster at 100 to 400 milligrams per day of luteolin, split morning and evening. Take it with a meal that contains fat — bile salts are what get the molecule out of the capsule and into circulation. The half-life is about five to seven hours Shimoi et al. 1998, which is why twice-daily dosing is the convention.

Give it twelve weeks before you decide whether it works. The mechanism the supplement is sold for — chronic mast-cell stabilization and microglial quieting — is not the kind of thing that acts in days. A three-week trial tells you almost nothing about whether the molecule is doing anything.

The interaction the label never warns about

Luteolin blocks a liver enzyme called CYP3A4 at sub-micromolar concentrations in human liver microsome assays Quintieri et al. 2011. CYP3A4 metabolizes about half of all common prescription drugs — most statins, cyclosporine and tacrolimus (transplant medications), many oncology drugs, several anticonvulsants, some psychiatric medications. The in-vivo clinical magnitude has not been formally quantified, but the in-vitro signal is potent enough that pairing luteolin with a narrow-therapeutic-index drug in that list is a real concern, not a theoretical one. Tell whichever clinician prescribes you anything that you are taking it.

What this is not

Luteolin is not lutein. Lutein is the yellow carotenoid in egg yolks and dark leafy greens that accumulates in the retina — a completely different molecule with completely different uses. The two share a Latin root (luteus, yellow) and almost nothing else. If you are trying to protect your eyes, you want lutein. If you are stabilizing mast cells, you want luteolin.
"Anti-inflammatory" is doing a lot of work in the marketing copy. Strong effects on inflammation in a cell dish at concentrations the supplement does not actually reach in your blood is the recurring flavonoid story Wang et al. 2021. Five servings of vegetables daily move your inflammation markers more reliably than 200 mg of any single flavone.
Eating more parsley is not equivalent to taking the supplement. Dietary luteolin from a salad is one or two milligrams a day. The supplement is a hundred to three hundred times that. They are different categories of intervention. The food version is dose-too-low to do what the supplement is sold to do; the supplement is too narrow-mechanism to replace what the diet does.
The famous human trials were not independent. Almost every clinical paper on luteolin for autism, mast-cell disease, or long-COVID brain fog traces to one investigator group with disclosed patent interests in the studied formulations. The cell and animal mechanism work has been done by many independent labs and is robust. The human trial work is concentrated in a way that ought to make you read it carefully.

Who this is actually for

Where the molecule is plausibly worth a careful trial:

Mast cell activation syndrome, chronic urticaria, or histamine intolerance not fully controlled by an H1 antihistamine plus an H2 blocker. The mechanism aligns most cleanly with this group, and the community signal — fewer flushes, fewer post-meal reactions, calmer skin — concentrates here.
Allergic rhinitis as an antihistamine adjunct, if you have already optimized the antihistamine and want to add something with mast-cell-stabilizing mechanism rather than escalating to a steroid spray.
Post-COVID brain fog with a histamine flavour — symptoms that worsen after meals, partially respond to antihistamines, track with flushing or rashes. This is mechanistic plausibility, not proven efficacy; the published clinical evidence is a paper arguing trials should happen, not a paper reporting that they did Theoharides et al. 2021.
Parents of autistic children considering an inflammation-targeted adjunct, with eyes open about the methodological limits of the trials this is based on — open-label, single-arm, multi-ingredient formulation, conducted by the patent-holder.

Where it is not for you: healthy adults wanting "general anti-inflammatory" coverage or a nootropic stack ingredient. The marginal effect over a Mediterranean-pattern diet is unknowable and almost certainly small. This is a niche tool. The mistake to avoid is treating it like a generalist one.

What works better, when it works

For histamine-driven symptoms, the first-line tools are cheaper, better-evidenced, and usually more effective:

H1 antihistamines — cetirizine, fexofenadine, loratadine. Generic, daily, decades of trial evidence. Try these first and titrate up before adding anything else.
H2 blockers — famotidine. Stacks on top of H1 for mast-cell-driven symptoms; cheap and well-tolerated.
Prescription cromolyn sodium — the strongest mast-cell stabilizer in clinical use. Oral cromolyn is off-label but standard practice for MCAS in specialist clinics. If your symptoms are bad enough to be searching for luteolin, you should be in front of someone who can prescribe this.
Quercetin — a related flavone with overlapping mast-cell-stabilizing literature and a separate (also thin) trial base. Often used alongside or instead. Caution if you are sensitive to catecholamines; quercetin blocks the enzyme that breaks them down.

For "I want less inflammation in general," the things with actual outcome trials behind them are exercise, sleep correction, weight loss, and a Mediterranean-pattern diet. Any of those moves the needle further than 200 mg of a flavone supplement.

For long-COVID cognitive symptoms specifically, there is no established treatment yet; the active trial landscape includes low-dose naltrexone, metformin, and several immunomodulators. Luteolin is one of the cheaper, safer things to try while the field figures itself out — that is the honest reason to consider it, not because anyone has shown it works.

On price: generic luteolin runs roughly $20 to $40 a month as plain capsules; the branded mast-cell formulations Theoharides' group helped develop are closer to $40 to $80 a month. Over a year of committed use that is the difference between a couple of hundred and nearly a thousand dollars — well into the territory where the absent RCT starts feeling expensive.

The five ways this doesn't work

Wrong formulation. Dry luteolin powder taken without fat barely makes it into your blood. The lipid carrier is doing half the work — without it you are mostly paying for excreted flavone.
Wrong indication. Taken for "general inflammation" or as a focus stack ingredient. The audience this molecule fits is narrow; most people who buy it are outside it and will (correctly) feel nothing.
Too short a trial. The proposed mechanism is chronic mast-cell and microglial quieting, not acute relief. Three weeks in, calling it for or against is reading noise.
Confounded stacking. Started the same month as a low-histamine diet, an antihistamine swap, or a DAO enzyme supplement. Whatever the luteolin is or isn't doing is now invisible inside three other variables.
Missed drug interaction. Started without telling the prescribing clinician, and now a statin level drifts up, or a tacrolimus blood draw comes back hot, or an anticonvulsant rides high. Avoidable, expensive, and the kind of thing the supplement label will never warn you about.

Related territory if this is where you are spending time:

Mast cell activation syndrome and chronic urticaria — the conditions this supplement was developed to target, where the rest of the clinical toolkit lives.
Quercetin — the related flavone with overlapping mast-cell evidence and its own trial base.
Cromolyn sodium — the prescription mast-cell stabilizer this supplement is meant to adjunct, not replace.
Long-COVID cognitive symptoms — the broader landscape of trials and adjuncts the brain-fog hypothesis sits inside.
The Mediterranean diet — where dietary luteolin intake is highest, alongside dozens of other polyphenols nobody is trying to sell you separately.

1. Substance + claimed effects

Luteolin (3',4',5,7-tetrahydroxyflavone) is a flavone — a yellow polyphenol — found in celery, parsley, thyme, oregano, peppermint, rosemary, sage, artichoke leaf, and chamomile, plus smaller amounts in carrots, green peppers, broccoli, and extra-virgin olive oil Lopez-Lazaro 2009. Habitual intake from a Western diet is on the order of a milligram or two per day, almost entirely as luteolin-7-O-glucoside; supplement doses are 100–300× higher, typically aglycone luteolin extracted from Sophora japonica or Reseda species Wang et al. 2021. The supplement claims four families of effect: (1) general anti-inflammatory activity via NF-κB and MAPK inhibition; (2) mast-cell stabilization with knock-on effects on allergic, autoimmune, and "neuroinflammatory" presentations (autism, brain fog, post-COVID cognitive symptoms); (3) cognitive / mood support framed as microglial quieting; and (4) metabolic improvement (insulin sensitivity, hepatic lipid handling). A fifth family — direct anticancer effect — is heavily preclinical and not in scope for a generalist supplement entry, but is acknowledged in §3. This entry covers (1)–(4) holistically; the centre of gravity is the mast-cell / neuroinflammation axis, where the human evidence (such as it is) is concentrated and where the supplement is actually marketed.

2. Evidence by addressing question

Mechanism

Science. Luteolin inhibits the transcription factor NF-κB by blocking IκB phosphorylation and p65 nuclear translocation, with downstream reductions in TNF-α, IL-6, IL-1β, COX-2, and iNOS in LPS-stimulated macrophages at low-micromolar concentrations Xagorari et al. 2002; the same NF-κB and MAPK (p38, JNK) targets are recapitulated across dozens of in-vitro and rodent models reviewed in Aziz et al. 2018. In microglia (the brain's resident macrophages), luteolin suppresses LPS-induced IL-6 by inhibiting JNK phosphorylation and AP-1 activation Jang et al. 2008 — the mechanistic basis of the "brain-fog" hypothesis.

Mechanism (mast cells). In cultured human cord-blood-derived mast cells and the HMC-1 line, luteolin inhibits IgE-mediated degranulation, blocking histamine, tryptase, TNF-α, and prostaglandin D₂ release at low-micromolar concentrations Kimata et al. 2000. It also blocks myelin-basic-protein-induced human mast-cell activation and downstream T-cell co-stimulation Kempuraj et al. 2008 — the mechanistic platform for the autism / MS / mast-cell-disorder framing. Theoharides' group developed a methoxylated analog (tetramethoxyluteolin / methoxyluteolin, sometimes branded "Lut08") that is ~10× more potent on mast cells in vitro and crosses the blood-brain barrier more readily Weng et al. 2015; commercial supplements remain plain luteolin.

Mechanism (cancer / longevity). Kinase inhibition (EGFR, PI3K/Akt, JAK/STAT3), pro-apoptotic effects via p53 stabilization, and downregulation of anti-apoptotic Bcl-2 are reported across cancer cell lines and xenografts Imran et al. 2019. Mechanistically coherent; in-vivo doses required are well above achievable plasma levels from oral supplementation in humans.

Pharmacokinetics — the mechanism's gating constraint. Free luteolin is poorly water-soluble; in rats and the small human series in Shimoi et al. 1998, an oral 25-mg luteolin dose produced peak plasma concentrations around 0.5–1 µM as glucuronide / sulfate conjugates, with a plasma half-life of ~7 hours. The aglycone — the form active in cell assays — circulates at much lower free concentrations. Comparative pharmacokinetics confirm luteolin exposure is several-fold lower than apigenin's after equivalent oral doses, due to extensive phase-II conjugation in gut and liver Chen et al. 2012. This means most in-vitro IC₅₀ values (1–50 µM) are not realistically achieved in human plasma at standard supplement doses, a gap routinely acknowledged in the dietary-luteolin reviews Wang et al. 2021. Lipid formulation (luteolin dissolved in olive-pomace oil, the basis of the NeuroProtek / PureLut product line) is the workaround the marketers lean on; absolute bioavailability gains are claimed but not rigorously quantified in published human PK.

Evidence

Science — human trials. Pure-luteolin RCTs in humans are sparse. The single most-cited human study is Taliou et al. 2013: an open-label, single-arm 26-week trial of a luteolin-quercetin-rutin formulation (NeuroProtek-like, 100 mg luteolin + 70 mg quercetin + 30 mg rutin per capsule, two capsules per 10 kg body weight per day) in 50 children with autism spectrum disorder; primary outcome was Aberrant Behaviour Checklist and adaptive function scores. 27 of 40 completers showed clinically meaningful improvements in adaptive function and overall behaviour. Same cohort, follow-up Tsilioni et al. 2015: responders had statistically reduced serum TNF and IL-6 versus non-responders, tying the behavioural effect to a measurable inflammatory readout. Both studies were open-label, single-arm, and from the same group with intellectual-property interest in the formulation; they are mechanistic plausibility, not efficacy evidence. A small open-label series in refractory interstitial cystitis using CystoProtek (luteolin + quercetin + other flavonoids) reported symptom reductions in ~58% of patients Theoharides et al. 2009; same methodological caveats.

Science — preclinical, well-replicated. Anti-inflammatory effects in rodent models of colitis, hepatic steatosis, allergic airway disease, and lipopolysaccharide-induced sickness behaviour are consistent across labs, reviewed in Aziz et al. 2018. Metabolic improvements — reduced adiposity, improved glucose tolerance, lower hepatic triglycerides — show up at dietary inclusion levels of 0.01–0.05% in mice Xu et al. 2014 and are reviewed mechanistically in Wang et al. 2021. Anticancer activity is broad and replicated across cell lines and many xenograft models Imran et al. 2019.

Practice / clinical. No major guideline (AAAAI, EAACI, AAP) recommends luteolin for any indication. It is not in the AAAAI's mast cell activation disorder workup; it is not in NICE allergy guidance. A subset of integrative / functional-medicine clinicians use luteolin formulations for MCAS, post-COVID brain fog, and ASD inflammation — mostly downstream of Theoharides' work; this practice is not represented in mainstream allergy or psychiatric consensus.

Community / lay evidence. Substantial. Reddit communities (r/MCAS, r/covidlonghaulers, r/Autism parents) report use of luteolin-quercetin stacks for histamine-mediated symptoms, brain fog, and post-exertional symptoms; reports are mixed — a fraction report clear symptom reduction (especially of histamine-flush, urticaria, and post-prandial flushing), most report subtle or null effects, a small minority report worsening (suggested mechanism: quercetin's COMT inhibition raising catecholamines). Volume is in the high thousands of posts but the signal is heterogeneous, contaminated by stacking (concurrent low-histamine diet, antihistamines, cromolyn) and by survivorship bias on the relevant subreddits. Not strong evidence of effect; reasonable evidence that some patients with mast-cell-mediated symptoms perceive benefit.

Protocol

Science. Doses used in human studies cluster at 100–400 mg/day of luteolin, usually as a lipid-emulsified formulation, taken with a fat-containing meal (the formulation's solubility depends on bile-stimulated micelle formation). Theoharides' formulations are dosed by body weight (~20 mg luteolin / kg / day in the autism trials); the same range as a flat-dosed supplement for an adult comes out to 200–400 mg/day split AM/PM. Half-life ~5–7 hours Shimoi et al. 1998 supports twice-daily dosing.

Practice. Functional-medicine protocols typically run 8–12 weeks before assessing response, since the proposed mechanism (chronic microglial quieting, mast-cell reservoir depletion) is not expected to act acutely. Stacking with quercetin (anti-mast-cell, COMT inhibitor — caution in some) and rutin (the luteolin glycoside's chemical relative, prolongs half-life by saturating glucuronidation) is the published formulation pattern. Plain luteolin powder dissolved in olive oil at home is sometimes recommended on enthusiast forums; bioavailability is unverified.

Contraindications

Drug interactions — CYP3A4. Luteolin (and the related flavone diosmetin) inhibit CYP3A4 and CYP3A5 in human liver microsomes and recombinant enzyme assays at sub-micromolar IC₅₀ Quintieri et al. 2011; CYP3A4 metabolizes roughly half of all clinically used drugs. Clinical-magnitude interactions have not been quantified in dose-controlled human PK studies, but the in-vitro inhibition is potent enough that concomitant use with narrow-therapeutic-index CYP3A substrates (cyclosporine, tacrolimus, several statins, midazolam, certain anticonvulsants, many oncology drugs) is plausibly clinically relevant. Real signal, under-studied.

Pregnancy / breastfeeding. No human safety data at supplement doses. Animal data are reassuring at dietary levels but not at concentrated supplement levels; conservative default is avoidance.

Anticoagulants. Flavonoids broadly have weak antiplatelet activity in vitro; luteolin specifically inhibits platelet aggregation in some assays. Practical signal in patients on warfarin or DOACs is unclear but warrants caution.

Other. Quercetin (often co-formulated) inhibits COMT; in catecholamine-sensitive patients (some MCAS, some POTS) this can drive symptoms. Not a luteolin effect per se but worth flagging in protocols.

Misconceptions

Luteolin is not lutein. Luteolin is a flavone polyphenol; lutein is a yellow-orange xanthophyll carotenoid found in egg yolks and dark leafy greens, accumulated in the macula of the retina. The names share a Latin root (luteus = yellow) and are confused in lay coverage. Different molecules, different uses, different evidence base.

"Anti-inflammatory" is doing a lot of work. Strong NF-κB inhibition in vitro at micromolar concentrations does not translate cleanly to a systemic anti-inflammatory effect at oral supplement doses in humans, because free luteolin plasma levels at standard doses are an order of magnitude below the in-vitro IC₅₀ and are dominated by glucuronide / sulfate conjugates with attenuated activity Wang et al. 2021. The cell-and-mouse-to-human gap is the dominant unknown.

Eating more parsley is not equivalent to supplementation. Dietary luteolin intake of 1–2 mg/day is 100–300× lower than supplement doses; the food sources are a real intake category but cannot deliver the mechanism the supplement is marketed for. Conversely, the supplement does not replace the broader benefits of a polyphenol-rich diet.

Theoharides' authorship clusters. Most luteolin-for-neuroinflammation literature traces to one investigator's group with disclosed patent interests in luteolin formulations (NeuroProtek, PureLut, Lut08). The mechanistic work is robust; the clinical trials sharing authors with the IP-holder are not independent replications.

Audience

Plausible niches with at least mechanistic support. (a) Mast cell activation syndrome (MCAS) patients seeking adjunct to H1/H2 antihistamines and cromolyn — community-level practice; small open-label evidence at the related-product level. (b) Histamine-driven allergic rhinitis seeking a supplement adjunct — preclinical mast-cell stabilization is the basis; no rigorous human RCT in AR. (c) Parents of autism-spectrum children considering an inflammation-targeted adjunct, with informed consent about the methodological limits of the source trials. (d) Long-COVID brain fog patients exploring options — explicitly framed by Theoharides et al. 2021 as mechanistic plausibility, not established efficacy.

Implausible audiences. Healthy adults seeking nootropic enhancement, longevity stacking, or "general anti-inflammatory" coverage; the marginal effect over diet is unknowable and almost certainly small. The supplement is poorly positioned as a generalist tool.

Alternatives

For mast-cell-mediated symptoms: H1 antihistamines (cetirizine, fexofenadine, loratadine) and H2 antagonists (famotidine) are first-line, evidence-supported, and cheap. Cromolyn sodium (oral, off-label for MCAS) is the prescription mast-cell stabilizer with the strongest mechanism alignment. Quercetin alone has overlapping mast-cell-stabilizing literature and is often used in parallel. For neuroinflammation framings: low-grade chronic inflammation is more reliably moved by exercise, sleep correction, weight loss, and Mediterranean diet than by any flavone supplement. For long-COVID brain fog specifically: there is no established pharmacological treatment; current trial landscape includes naltrexone, metformin, and various immunomodulators, none with luteolin's combination of cheap+benign safety profile.

Failure-modes

Wrong formulation. Cheap luteolin powder taken without fat is poorly absorbed; placebo response to "I'm taking something" is the most likely effect at low effective bioavailability.

Wrong indication. Tried for "general inflammation" or as a nootropic — the population the entry is plausibly for is narrow, and most users fall outside it.

Too short a trial. Mechanism (chronic microglial / mast-cell reservoir effects) is slow; sub-4-week trials are uninformative.

Confounded stacking. Concurrent low-histamine diet, antihistamines, or DAO supplementation make the supplement's marginal effect impossible to read.

Missed drug interaction. CYP3A4 inhibition not flagged to prescribing clinicians, with potential to raise levels of co-administered statins, immunosuppressants, or anticonvulsants.

3. The credibility range

Optimist case

Luteolin has one of the best-characterized mechanistic stories in the flavonoid literature: replicated inhibition of NF-κB, MAPK p38/JNK, COX-2, iNOS, and IgE-mediated mast-cell mediator release across dozens of independent labs Aziz et al. 2018 Kimata et al. 2000. The microglial-JNK / IL-6 mechanism Jang et al. 2008 provides a coherent biological basis for the "neuroinflammation" framing that long-COVID brain fog and ASD literatures have converged on. Two open-label human trials show clinically meaningful behavioural improvement in autism that tracks reductions in inflammatory cytokines Taliou et al. 2013 Tsilioni et al. 2015; the mechanism-biomarker-behaviour chain is unusually complete for a flavonoid. The supplement is cheap, well-tolerated, and reaches indications (mast-cell stabilization, microglial quieting) where the mainstream pharmacological toolkit is weak or absent. Mast-cell-mediated brain fog is a real, emerging clinical entity; a flavone with replicated in-vitro mast-cell stabilization and reasonable CNS exposure is a credible adjunct option pending better trials.

Skeptic case

Despite 20+ years of mechanistic literature, there is not a single placebo-controlled, blinded, adequately powered human RCT of luteolin demonstrating efficacy on any clinical endpoint. The two human trials cited as evidence Taliou et al. 2013 Tsilioni et al. 2015 are single-arm, open-label, conducted by an investigator with disclosed patent interest in the studied formulation, and use a multi-component product (luteolin + quercetin + rutin) — they cannot attribute effect to luteolin and cannot rule out placebo, regression-to-the-mean, or developmental progression in young children. Pharmacokinetics is the structural problem: free luteolin plasma levels at standard supplement doses sit roughly 10× below the IC₅₀ for most reported anti-inflammatory effects Wang et al. 2021 Chen et al. 2012, and circulating conjugates have markedly attenuated activity. The "long-COVID brain fog to the rescue" framing Theoharides et al. 2021 is mechanistic speculation marketed as a clinical recommendation. Anticancer effects are entirely preclinical at doses unachievable in humans. The supplement industry's monetization of a thin evidence base — branded formulations at $40–80/month for components the trials have not shown to work individually — is a clear commercial signal.

Author's call

Lands skeptical-but-not-dismissive. Luteolin is a real molecule with a real mechanism, narrowly useful in specific niches (mast-cell-mediated symptoms, possibly histamine-driven brain fog), and reasonable to try as an adjunct when first-line tools have been tried and the patient and clinician have set realistic expectations. Not a general anti-inflammatory, not a nootropic, not a longevity stack component. Evidence rating reflects the structural absence of blinded RCTs (≤2/5); controversy is modest (the niche claims are mechanistically defensible — disagreement is about how much you can extract from open-label trials, not whether the molecule does anything in cells). The catalogue's posture: clear-eyed about the gap between in-vitro / mechanism and human clinical effect, honest about who has plausible reason to try it, blunt about the CYP3A4 interaction risk that the marketing copy never mentions.

4. Stakeholder + incentive map

Commercial — branded formulation makers. Algonot LLC and related entities sell NeuroProtek, PureLut, FibroProtek, and CystoProtek; they retain or licence patents tied to Theoharides' work. Direct-to-consumer marketing leans on autism, mast-cell, and long-COVID framings.
Academic — Theoharides group at Tufts / Nova Southeastern. Highest-volume publisher in this space; disclosed IP interest. Mechanistic work is strong; their clinical trials of their own product are the weakest part of the literature.
Functional-medicine practitioners. Use luteolin formulations for MCAS, long-COVID, and ASD inflammation; not represented in mainstream allergy or psychiatry guidelines.
Mainstream allergy / immunology. Silent on luteolin. AAAAI, EAACI, and NICE do not mention it.
Community. r/MCAS, r/covidlonghaulers, autism-parent forums, integrative-medicine communities. Volume of discussion is high; consistency of reported effect is modest.
Skeptics. Quackwatch-style critics flag the same patent-author overlap and absent RCTs; mainstream evidence-based-medicine outlets either don't cover luteolin (it has not crossed the relevance threshold) or treat it as an example of preclinical-to-clinical overreach.

5. Population variability

MCAS / histamine-intolerant patients. The subpopulation most likely to perceive a real effect; mechanism aligns, community signal concentrates here.
Quercetin co-administration sensitivity. A non-trivial fraction of MCAS / POTS patients tolerate quercetin poorly (catecholamine-driven symptoms via COMT inhibition); these patients should seek luteolin-monotherapy formulations or skip the stack.
Children with autism spectrum disorder, parent-administered. The Taliou cohort showed responders (~58% of completers) and non-responders; predictors of response are not characterised.
Older adults on polypharmacy. CYP3A4 interaction risk concentrates here; statin and tacrolimus / cyclosporine users especially.
Pregnancy / lactation. No human data; default avoidance.
Generally healthy adults. Expected effect approaches zero above the diet baseline; the supplement is not for this population.

6. Knowledge gaps

What hasn't been done. A placebo-controlled, blinded, adequately powered RCT of pure luteolin (not a multi-component formulation) at a documented bioavailability-corrected dose, on a defined clinical endpoint in MCAS, chronic urticaria, or long-COVID cognitive symptoms. The two-decade absence of this trial is the central evidence gap.

What can't easily be done. Bioavailability-corrected dosing — until human PK is rigorously characterised for the lipid-emulsified formulation, "200 mg orally" is shorthand for an unknown plasma exposure. The methoxyluteolin analog Weng et al. 2015 would solve part of this but is not a commercial supplement.

What would change the call. A blinded RCT in MCAS or chronic urticaria showing significant symptom reduction over placebo would move evidence from 2 to 3 and the recommendation from "decide" to "do" for the niche audience. A negative RCT would move it to 1 and reframe the entry as primarily an alternatives / misconceptions piece. A documented clinical CYP3A4 interaction would tighten contraindications materially.

Surfaces this dossier could feed. An MCAS umbrella entry (drawing on the mast-cell-stabilizer evidence here); a quercetin entry (overlapping mechanism, separate evidence base); a long-COVID brain-fog entry (drawing on the neuroinflammation lens); a "supplement bioavailability — when in-vitro lies" methodology piece.

Narrowing relative to the brief. The brief named inflammation, cognition, mast-cell / allergic response, and metabolism. The article covers the first three substantively (inflammation in mechanism, cognition / brain fog in mechanism + audience, mast-cell / allergic in mechanism + evidence + audience). Metabolism is deliberately under-covered: the data is rodent diet-induced obesity at 0.01–0.05% dietary inclusion Xu et al. 2014 with no human translation, and giving it equal weight would mislead the reader about what is actually known. Flagged in the research dossier's §3b mechanism and §6 knowledge gaps; not given an addressing section in the article.

Score adjustments after first draft. Initial scoring had beauty_cumulative and longevity at 1 each on mechanism-plausibility grounds (anti-inflammatory NF-κB, metabolic rodent data). On article-coverage check, neither earned a paragraph in the body that survived the friend test — the honest line about both is "mechanism implies a nudge, no human evidence shows one." Dropped both to 0 rather than pad the article with thin paragraphs the reader could see through. mood kept at 1 because the autism trial behavioural endpoint is at least mood-adjacent and the evidence section actually engages with it.

Hard scoping calls.

Did not write a stakes or payoff section. The audience section does the work both would: who plausibly benefits and what the realistic upside looks like. Forcing felt-experience forecasts at a 2/5 evidence rating would have read like exactly the marketing voice the entry is critiquing.
Did not write a history section. Theoharides' research and patent history is the obvious target, but it lives more honestly in misconceptions (the trial-author overlap) and the research dossier's stakeholder map.
Did not use audience-scoped sub-blocks. The audience section is bulleted by user-segment but each segment is short enough that the markup overhead wasn't earning anything; a paragraph-level audience block would have been better for a longer treatment.

Rating difficulties.

controversy: 2 is a call between "mainstream silence + community use" (could read as a 1) and "patent-IP overlap + replicated PK skeptic case" (could read as a 3). Landed at 2 because the disagreement is more "is the evidence enough" than competing camps with different evidence.
evidence: 2 over 1. There is mechanism-biomarker-behaviour coherence in the autism cohort and dense replicated preclinical work; a flat 1 would understate that. But the absence of any blinded RCT keeps it well below 3.
cost_burden: edge case between 1 and 2. Generic capsules at the cheap end land closer to $100/year (a 1); branded mast-cell formulations push $700–900/year (a 2). Took the higher end because the audience this entry is for tends to gravitate toward the branded formulations.

Contraindications. Only pregnancy and breastfeeding tokens. The CYP3A4 interaction is the bigger real-world signal but the closed contraindication vocabulary has no token for it — covered prominently in body prose instead. Worth proposing a cyp3a4-substrate or narrow-therapeutic-index-meds token: this interaction recurs across the catalogue (quercetin, grapefruit, St John's Wort, several others).

Dream narrative. Computed overall score ≈ 11; well below the 40 threshold where a narrative is obligatory. Wrote a brief one anyway since the tool accepts and persists it; it leans the relief lever (clarity, not aspiration) and explicitly tells the dek / tagline writer not to overshoot. The dek and tagline were written straight per spec.

Future-link candidates.

Mast cell activation syndrome (MCAS) — the umbrella condition entry this should cross-link to once it exists.
Quercetin — overlapping flavone with its own separate trial base; obvious sibling.
Cromolyn sodium (oral, for MCAS) — the prescription this is positioned to adjunct.
Long-COVID cognitive symptoms / brain fog — the umbrella where the neuroinflammation hypothesis lives.
Chronic urticaria — distinct from MCAS, overlapping treatment menu.
CYP3A4 interactions in supplement-drug combinations — methodology piece the contraindications section gestures at.

Separate-entry candidates.

Quercetin warrants its own entry (similar evidence shape, larger trial base, different stakeholder profile).
An MCAS condition entry is the larger umbrella this should sit under.